Children Health

FDA review appears to pave the way for Pfizer-BioNTech vaccine for children 5 to 11

In the company briefing document, Pfizer and BioNTech argue that authorization of a coronavirus vaccine for children in this age group “could prevent harms that include, not only interruption of education, but also hospitalization, severe illness, long-term sequelae, and death. In addition, vaccinating this population will likely reduce community transmission, including transmission to older and more medically vulnerable individuals.”


Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button